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Abstract
Objective:Children in the child welfare system are the most expensive child population to insure for their mental health needs.
The objective of this article is to estimate the amount of Medicaid expenditures incurred from the purchase of psychotropic
drugs – the primary drivers of mental health expenditures – for these children.
Methods: We linked a subsample of children interviewed in the first nationally representative survey of children coming into
contact with U.S. child welfare agencies, the National Survey of Child and Adolescent Well-Being (NSCAW), to their
Medicaid claims files obtained from the Medicaid Analytic Extract. Our data consist of children living in 14 states, and
Medicaid claims for 4 years, adjusted to 2010 dollars. We compared expenditures on psychotropic medications in the
NSCAW sample to a propensity score-matched comparison sample obtained from Medicaid files.
Results: Children surveyed in NSCAW had over thrice the odds of any psychotropic drug use than the comparison sample. Each
maltreated child increased Medicaid expenditures by between $237 and $840 per year, relative to comparison children also
receiving medications. Increased expenditures on antidepressants and amphetamine-like stimulants were the primary drivers of
these increased expenditures. On average, an African American child in NSCAW received $399 less expenditure than a white
child, controlling for behavioral problems and other child and regional characteristics. Children scoring in the clinical range of the
Child Behavior Checklist received, on average, $853 increased expenditure on psychotropic drugs.
Conclusion: Each child with child welfare involvement is likely to incur upwards of $1482 in psychotropic medication
expenditures throughout his or her enrollment in Medicaid. Medicaid agencies should focus their cost-containment strategies
on antidepressants and amphetamine-type stimulants, and expand use of instruments such as the Child Behavior Checklist to
identify high-cost children. Both of these strategies can assist Medicaid agencies to better predict and plan for these
expenditures.
Introduction
Child abuse and neglect are major public healthchallenges in the United States today. This is because their
health and mental health sequelae are manifest not only during
childhood (Gilbert et al. 2009) but also persist long into adulthood,
being associated with a range of adverse adult health outcomes
(Felitti et al. 1998). Child abuse and neglect are also numerically
significant problems; in federal fiscal year 2009, *6,000,000
children were reported to child welfare/child protection agencies
(hereafter, child welfare) nationwide for suspected child maltreat-
ment (U.S. Department of Health and Human Services et al. 2010),
of whom almost half have clinically significant emotional or be-
havioral problems (Burns et al. 2004; Hurlburt et al. 2004). Med-
icaid is the dominant insurer of children in child welfare settings
(Raghavan and Leibowitz 2007). Quantifying and identifying the
drivers of such expenditures is of critical importance to Medicaid
agencies, especially at a time when the recession has expanded
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Medicaid enrollment nationwide and has increased pressure upon
the program (U.S. Department of Health and Human Services and
Centers for Medicare and Medicaid Services 2011), and when state
budgets are highly constrained.
Prescription drugs used for the treatment of mental disorders
(psychotropic drugs) are the principal drivers of the increase in
mental health spending, accounting for 51% of per capita spending
on mental health services (Frank et al. 2009). The implications of
this are particularly salient for Medicaid agencies, which pay for
psychotropic drugs for children in child welfare. For a variety of
reasons including the emotional and behavioral consequences of
maltreatment, and differences in access to psychosocial interven-
tions, children in child welfare receive psychotropic medications at
a rate between two and three times that of comparable children in
the community (Raghavan et al. 2005). Approximately one in seven
children in foster care receives a psychotropic drug at a given point
in time (Zima et al. 1999, 2000), a rate that rises to nearly one in
four when children in child welfare are followed up over time
(Leslie et al. 2010). Not only do these children receive more drugs,
they also receive more drugs concomitantly (Raghavan and
McMillen 2008; Zito et al. 2008). Cumulatively, children in the
child welfare system are the largest consumers of psychotropic
drugs of all child populations in the United States today.
From a Medicaid perspective, this pattern of psychotropic drug
use among child welfare populations has serious fiscal conse-
quences. Direct and indirect mental health costs can reach $16,848/
month for maltreated children (Conrad 2006), and total behavioral
health expenditures incurred by each child in foster care are more
than eight times higher than expenditures on non-foster children
(Becker et al. 2006). What is not well known is the extent to which
psychotropic medications are responsible for these expenditures,
and the particular classes of drugs most likely to contribute to them.
Identifying specific drugs (either by indication or pharmaceutical
class) has direct policy implications. If expenditures are being
driven by drugs used to treat a particular condition, Medicaid
agencies can construct disease management programs that target
such conditions. Also, if expenditures are driven by particular drug
classes, Medicaid agencies can expand their use of regulatory
mechanisms such as prior authorization (Tilly and Elam 2003) in
order to ensure cost containment.
In addition to identifying specific drugs, it is also important to
identify child characteristics that might increase the risk of Med-
icaid spending on these drugs. Currently, child-serving agencies
use a range of psychological instruments to assess the behavioral
needs of the child; Missouri’s Medicaid agency, for example, is
about to deploy an instrument called the Child Behavior Check List
(CBCL; described subsequently) (Achenbach 1991,1992) for all of
its child beneficiaries. The fiscal utility of such instruments is as yet
unknown. If increased scores on the CBCL are associated with
increased expenditures, for example, then this is valuable infor-
mation that Medicaid agencies can use to better predict their drug
expenditures, a technique called risk adjustment (Iezzoni 2003;
Blumenthal et al. 2005). This lack of data has been identified as one
of the principal challenges facing Medicaid agencies in their at-
tempts to contain costs of care for their child welfare beneficiaries
(Raghavan 2010).
This study was the first to link data from a national panel survey
of children and adolescents coming into contact with child welfare
agencies to their Medicaid claims. We quantified Medicaid ex-
penditures on psychotropic medications among these children, and
compared them to a propensity score-matched comparison sample
of child Medicaid beneficiaries without any Medicaid codes for
eligibility based upon foster care status. We modeled expenditures
for both of these groups to identify differential drivers of expen-
ditures, and ended by modeling expenditures among a sample of
child welfare-involved children. Through such analyses, we pro-
vide Medicaid agencies with information designed to help them
anticipate, better predict, and deliberately plan for mental health
expenditures for their child welfare-involved beneficiaries.
Methods
Data sources and creation of analytic data set
The National Survey of Child and Adolescent Well-Being
(NSCAW) is the first nationally representative, panel study of
children and adolescents coming into contact with child welfare
agencies. This probability sample contains data on 5501 youth
investigated by Child Protective Services for possible abuse and
neglect in 92 primary sampling units in 97 counties throughout the
United States. These data were obtained after interviews with
caregivers, caseworkers, teachers, and the youth themselves.
NSCAW’s baseline wave was conducted over a 15-month period
beginning October 1999 (NSCAW Research Group 2002; Dowd
et al. 2006), and these data were used for information on child and
caregiver characteristics. NSCAW contains information not only
on children placed in foster care (*11% of the sample), but also on
children who receive services while living in their birth homes.
NSCAW data, therefore, are designed to be representative of all
children who present to child protection agencies for suspected
maltreatment.
We obtained Medicaid claims files (Medicaid Analytic Extract
or ‘‘MAX’’ [Research Data Assistance Center 2011]) for years
2000 through 2003; enrollment files contained Social Security
Numbers (SSNs) and residence data of beneficiaries. These years
were chosen to parallel the time frame of NSCAW administration.
We obtained data on 14 states (Texas, Ohio, Florida, California,
Pennsylvania, New York, and eight others; our confidentiality
agreements preclude our identifying these states). These states were
chosen to maximize the number of NSCAW participants within that
state, the ‘‘yield’’ of SSNs within NSCAW, and the rate of managed
care penetration within that state. We also took into account the
availability of encounter data for Medicaid plans compensated
under a non-fee-for-service (FFS) payment methodology in each of
these states (‘‘shadow claims’’).
We first used SSNs to link NSCAW children to their MAX
personal summary file, which contains limited sociodemographic
information for beneficiaries; we were able to link 1557 NSCAW
youth to their Medicaid enrollment files. An additional 1259
NSCAW youth were linked after finding all unique date of birth,
sex, and ZIP code combinations that matched between NSCAW
and Medicaid enrollment files. Combinations with multiple mat-
ches are excluded from this study. The total linked NSCAW-MAX
sample was 2816 children. Other children in NSCAW could not be
linked either because their caregivers did not permit data linkage, or
because these children did not possess Medicaid personal summary
files. Linked and non-linked children were not statistically differ-
ent by age, gender, or placement category. More Hispanics
(19.9% vs. 15.2%, p< 0.001) were found in the linked sample, and
correspondingly fewer white, non-Hispanics (38.8% vs. 43.9%,
p< 0.001).
We linked these personal summary files to drug claims files (RX
file) across 4 years using unique research identifiers and aggregated
individual claims by beneficiary so that all claims within a single
calendar year captured all Medicaid expenditures on medications
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that year for a given NSCAW youth. We deleted from our sample
all children < 2 years of age at wave 1, because the version of the
CBCL (Achenbach 1991, 1992), the measure of need for mental
health services used in NSCAW, is not normed for that age group.
Except where otherwise noted, all NSCAW variables were ob-
tained from a caregiver report on the child. Children who were not
enrolled in an FFS or primary care case management (PCCM) plan
for a full year were also deleted, as we observe only enrollment, not
claims or services, for children in Medicaid managed care.
We generated a comparison sample of putatively non-child
welfare-involved Medicaid beneficiaries using propensity score
matching, with replacement, to the nearest neighbor (Guo and
Fraser 2010). We identified a cohort of Medicaid beneficiaries
without any Medicaid codes for eligibility based upon foster care
status, and then matched them to NSCAW children using their age,
gender, race/ethnicity, year of data, Medicaid plan type (FFS,
PCCM, or both in a calendar year), and ZIP code of residence. We
conducted sensitivity analyses using 1:1 and 1:10 matches, but the
increase in precision was negligible, and we present results from
the 1:1 matched comparison sample. Eligibility codes were dis-
tributed proportionately between the NSCAW and matched sam-
ples for most categories, except for foster care (exclusively
NSCAW by design) and State Children’s Health Insurance Pro-
gram (SCHIP) (46% matched vs. 29% NSCAW). Deletion of
children < 2 years of age was conducted after matching, so the final
sample is slightly unbalanced: 2831 NSCAW and 2821 matched
child observations, for a total of 5652 child observations over 4
years for both NSCAW and the matched samples.
Medicaid expenditures on psychotropic medications
Because each Medicaid drug claim contains information on a
particular formulation and packaging of a particular drug, we ag-
gregated these data for ease of understanding using two approaches.
First, we used codes from Medicaid RX (MRX) (Gilmer et al.
2001), the most widely used Medicaid pharmacy risk adjustment
model, to aggregate drugs by indications for attention-deficit dis-
order, depression/anxiety, psychotic illness/bipolar, and seizure
disorder (which contains anticonvulsants that are sometimes used
in the treatment of psychiatric illnesses). Second, we used drug
categories from the Red Book (Thompson Reuters 2011) in order to
present information on drug classes of relevance to psychiatric
practice. Red Book is an industry-standard reference that contains
details on, among other things, drug (pharmaceutical) classes.
Taken together, these approaches allow examination of the types of
medications used, and the indications for which they are used. We
purposively selected mental health-relevant MRX and Red Book
categories; therefore, results from these two approaches are not
expected to be equivalent. Outcomes for both groupings were
measured as annual utilization, defined as any non-zero Medicaid
expenditures in a calendar year, and mean total annual Medicaid
expenditure per child. Out of pocket expenditures and other payers
are not available in MAX data.
Covariates
Child-level covariates included child age, gender, and race/
ethnicity, all as coded in the NSCAW data. Identification of be-
havioral problems was based on the identification of a probable
behavioral disorder if the child scored in the clinical range (t score
‡ 64) on the internalizing or externalizing scales of the CBCL
(Achenbach 1991, 1992), a caregiver-elicited questionnaire that is a
well-established measure of mental health need among child wel-
fare populations (Raghavan et al. 2005, 2010a, b). Maltreatment
history was obtained from the child’s child welfare caseworker and
was based on a modified Maltreatment Classification Scale (Manly
et al. 1994). Categories of physical abuse, sexual abuse, neglect,
and abandonment were dichotomized such that a child could have
more than one type of abuse coded. We also used a binary indicator
variable representing ‘‘fair’’ or ‘‘poor’’ physical health, with ‘‘ex-
cellent, ‘‘very good,’’ or ‘‘good’’ as a referent, reported by the
child’s caregiver; these questions have been used by the National
Health Interview Survey since 1982 (Adams et al. 1999).
Each child’s placement status was grouped into two mutually
exclusive categories of in-home (i.e., living with their permanent
primary caregiver, usually their birth parent), or out-of-home (in
family foster care – either with a relative or nonrelative – or in
congregate care, such as a group home or residential treatment
center). Information on whether the child lived in an urban or rural
area was obtained from NSCAW data as a control for the availability
of healthcare resources in the child’s community. We also included
dummy variables for insurance type (FFS, PCCM, or both types)
from the Medicaid enrollment files. All covariates were measured at
baseline, except insurance type, which was measured at the child
observation (i.e., calendar year) level for an individual child.
Analyses
We first obtained an aggregate expenditure figure per child per
year, for both NSCAW and comparison samples, and adjusted all
expenditures to 2010 dollars following guidelines from the Agency
for Healthcare Research and Quality (U.S. Department of Health
and Human Services, Agency for Healthcare Research and Quality
2011) and Centers for Medicare and Medicaid Services (U.S.
Department of Health and Human Services et al. 2008) (details
available from the authors upon request). Bivariate analyses
showing mean differences in rates of annual use of, and expendi-
tures on, psychotropic medications between NSCAW and com-
parison group children were performed using a two-sample t test,
after summing use and expenditures over all years.
Differences in psychotropic medication expenditures between
NSCAW and comparison group children were then examined using
a two-part (Duan et al. 1984) generalized linear model (GLM) that
used expenditures per child per year as its outcome. In the first part
we used logistic regression to estimate the annual probability of
having any medication expenditures, and in the second part we used
a generalized linear model with a log link and a c distribution
(essentially a regression model of log annual expenditures among
children with non-zero expenditures), as suggested by Manning and
colleagues for expenditure data (Manning et al. 2003, 2005). These
models used 5652 child observations. We then focused only on
NSCAW children and estimated similar models on this sample
(2096 child observations after some missing values) to examine the
association between NSCAW’s rich set of explanatory variables
and expenditures. We developed predictive margins (Graubard and
Korn 1999) for significant coefficients from the second part of our
models in an attempt to increase their interpretability; predictive
margins of expenditures for an African American race/ethnicity
coefficient, for example, is the average difference in expenditures
between African American children and whites, controlling for the
other variables in the model.
Although the NSCAW data come with a set of survey weights,
we report unweighted expenditure data for two reasons. First, a full
complement of survey weights comparable to NSCAW is not
available for our comparison sample, which is obtained from MAX
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files alone. Second, our outcome variable is an annualized expen-
diture derived from Medicaid claims (not NSCAW), and hence
NSCAW weights cannot be applied to these exogenous data. In an
attempt to reduce bias and the risk of a type 1 error, however, all
models include corrections for the clustering of multiple years’
worth of expenditure observations per child. Confidence intervals for
all expenditure estimates were bootstrapped using a bias-corrected
empirical model with 1000 replications. We also include state fixed
effects to control for unobserved state-level variables that might
affect expenditures for all children within a given state, and year-
fixed effects to control for secular trends (not shown in tables).
All analyses were performed in Stata version 12.0 (StataCorp
2010).
Results
Among the NSCAW youth, 1350 (47.7%) were male. At
NSCAW’s baseline wave, 997 (35.2%) were aged between 2 and 5
years, 990 (35.0%) between 6 and 11 years, 305 (10.8%) between
12 and 13 years, and 539 (19.0%) > 14 years. Most children (1491,
52.7%) were of non-Hispanic white race/ethnicity, others were
African American (941, 33.2%), and the remainder were of un-
known race/ethnicity (135, 4.8%).
Table 1 shows bivariate analyses of the mean differences in
utilization of, and annual expenditures on, psychotropic medica-
tions between NSCAW and comparison group children. Prescrip-
tions in the MRX classifications shown were used by 26% (735
child observations) of the NSCAW sample versus 11% (306 child
observations) of the comparison sample ( p < 0.001). Among those
who received these medications, mean drug expenditures for
NSCAW children were significantly higher ($1482) than those of
children in the comparison group ($993; p< 0.001). NSCAW
children had significantly higher use and expenditures for drugs
used to treat attention-deficit, and depression/anxiety disorders than
did children in the comparison group ( p= 0.002 and p= 0.003), as
well as increased utilization of drugs used to treat psychotic/bipolar
disorders ( p< 0.001) whereas other categories were not signifi-
cantly different.
Results of differences in pharmaceutical class (Red Book clas-
sifications) were similar, with rates of 28% and 14% for differences
in use, and expenditure differences of $1368 and $784, for NSCAW
compared to non-NSCAW children respectively ( p< 0.001 for
both). Expenditure differences were observed on antidepressants
($551 for NSCAW versus $395 for non-NSCAW; p = 0.007),
amphetamine-type stimulants ($593 versus $494; p = 0.02), and
miscellaneous central nervous system agents – a grouping that in-
cludes drugs such as clonidine ($518 versus $218; p = 0.04).
Differences in cumulative drug expenditures between NSCAW
and comparison group children are reported in Table 2. Odds ratios
(OR) from Part 1 of the model indicate the likelihood of annual
Table 1. Utilization Rate and Mean Expenditures Among Individuals Using Each Type
of Medication (nT = 5652 Child Observations)
NSCAW sample Comparison sample
Utilization Utilization
Drug nT= 2831 (%) Expenditure ($) nT = 2821 (%) Expenditure ($)
MRX classification
Attention-deficit disorder 16.32*** 626** 7.05 492
Depression/anxiety 12.89*** 550** 4.29 379
Psychotic illness/bipolar disorder 8.72*** 1790 18.08 1783
Seizure disorders 6.64*** 838 2.38 1033
Total for any of these 25.96*** 1482*** 10.85 993
Red Book classification
Sedatives/hypnotics, barbiturates 0.49 103 0.25 87
Sedatives/hypnotics, benzodiazepines 0.60 78 0.78 252
Anticholinergic/antimuscarinic/antispasmodic 0.81 136 0.92 46
Anticholinergic/antiparkinsonian agent 0.60*** 85 0.07 28
Anticholinergic, not elsewhere classified 0.28 125 0.24 76
Anticonvulsants, hydantoin derivative 0* – 0.14 229
Anticonvulsants, oxazolidinediones 0 – 0 –
Anticonvulsants, succinimides 0 – 0.04 792
Anticonvulsants, benzodiazepines 0.39 186 0.14 151
Anticonvulsants, miscellaneous 6.39*** 862 2.20 1,002
Antimanic agents, not elsewhere classified 0.71** 234 0.14 300
Anxiolytics/sedatives/hypnotics not elsewhere classified 4.13* 91 3.08 49
Central nervous system agents, miscellaneous 1.41*** 518* 0.39 218
Opiate antagonists, not elsewhere classified 0.04 894 0 –
Antidepressants 12.22*** 551** 3.86 395
Antipsychotics 8.51*** 1815 1.81 1759
Stimulants, amphetamine type 16.00*** 593* 6.91 494
Stimulants, non-amphetamine 0 – 0.04 360
Total for any of these 28.44*** 1368*** 14.04 784
*Significant at < 0.05, **significant at < 0.01, ***significant at < 0.001.
MRX=Medicaid Rx, NSCAW=National Survey of Child and Adolescent Well-Being; nT= child-year observations.
Note: Utilization is the row mean and is non-exclusive; therefore, the sum may exceed the MRX or Red Book total. Expenditures reflect means for
observations of children who are using a particular type of medication. Zeros are not included in the means.
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utilization of any of the MRX categories in Table 1 and, conse-
quently, the odds of having any expenditures on any psychotropic
medications. (In an attempt to avoid redundancy, we do not show
expenditure differences for the Red Book classifications.) Con-
trolling for demographic and insurance characteristics, an NSCAW
child had over thrice the odds of incurring an expenditure on any
psychotropic drug than did a non-NSCAW child (OR: 3.4; 95%
confidence interval [CI]: 2.8, 4.2; p< 0.001). Across both groups,
older children and males had significantly higher odds of incurring
any expenditures, whereas children in Medicaid plans that used
PCCM as a reimbursement modality had* 30% lower odds of any
expenditure than did children in Medicaid plans that paid using
FFS. When compared with white children, children of African
American race/ethnicity had approximately half the odds of in-
curring expenditures on any medications (OR: 0.6; 95% CI: 0.4,
0.7; p< 0.001).
Table 2 also displays coefficients of the GLM model (Part 2)
showing predictors of expenditure among children with any (non-
zero) expenditures on psychotropic drugs. The direction of these
predictors parallels that of Part 1 of the model. Among only those
with positive expenditure in these MRX categories, the GLM co-
efficients imply that African American children have a mean dif-
ference of $399 (95% CI: $2, $796; p = 0.05) less expenditure than
white children. Being Hispanic or other/unknown race/ethnicity
was not significantly associated with utilization or expenditure. A
child whose Medicaid program reimbursed providers on a PCCM
basis incurred $577 less in expenditures (among those with positive
expenditure) than did a child whose Medicaid program paid its
providers on an FFS basis (CI: $125, $1028, p = 0.01).
Table 3 displays results that are from a two-part model of dif-
ferences in psychotropic medication expenditures conducted on a
stratified sample of NSCAW-only children. As seen in the table,
males and older children had significantly higher odds of use and
expenditures of any psychotropic medication than did girls and
younger children. Furthermore, NSCAW children in out-of-home
placement (compared with children maintained in-home), those in
fair or poor health, those with externalizing CBCL in the clinical
range, and those with a physical abuse history all had higher odds of
incurring any expenditure for drugs in the MRX categories. How-
ever, as seen in Part 2 of this model, only a clinically significant
externalizing CBCL score was a significant predictor of expendi-
tures for children with non-zero expenditures. A CBCL t score ‡ 64
was associated with an $853 increase in psychotropic medication
expenditures among children with non-zero expenditures (CI: 366,
1340, p= 0.001). An African-American child in NSCAW incurred
$760 lower expenditures than did a white child, controlling for the
other variables in the model (CI: 239, 1281; p= 0.004).
Discussion
In this study, we examine Medicaid expenditures on psycho-
tropic drugs among a sample of child respondents to the NSCAW,
in 14 states. NSCAW children had three times the odds of using
medications, and incurred between 50% and 75% higher expendi-
tures on medications (Table 1) than did Medicaid child enrollees
without apparent child welfare involvement. Each maltreated child
enrolled into Medicaid increased the program’s expenditures on
psychotropic medications by between $489 (differences between
Medicaid RX estimates) and $584 (Red Book estimates) per year,
relative to non-maltreated children also receiving these medica-
tions. These estimates provide greater precision than did prior at-
tempts to identify the magnitude of incurred expenditures on this
population, and allow state Medicaid policy makers to calculate
provisional budgets on a per-child per-year basis that can ade-
quately resource their medication use needs, or to set capitation
rates for medication management contracts.
Medicaid agencies not only need to budget for these expendi-
tures annually, but also to take into account cumulative expendi-
tures incurred by these children during their stay within the child
welfare system over time. Children in foster care who are
Table 2. Two-Part Regression Model of Cumulative Drug Expenditures (MRX Classification),
NSCAW Versus Comparison Sample (nT= 5652 Child Observations)
Part I: Odds ratio
(95% CI) for
any expenditure
Part II: GLM coefficients
(95% CI) for
expenditure if > $0
Predictive margin
(Part II) for
expenditure if > $0 ($)
NSCAW sample 3.40 (2.78, 4.15)*** 0.40 (0.19, 0.61)*** 538.73 (236.98, 840.48)
Male 1.65 (1.33, 2.03)*** 0.32 (0.11, 0.54)** 431.23 (131.15, 731.31)
Age
3–5 (omitted) (omitted)
6–11 7.81 (5.75, 10.59)*** 0.71 (0.30, 1.11)** 943.55 (387.91, 1499.20)
12–13 10.58 (7.46, 15.01)*** 0.96 (0.53, 1.39)*** 1283.02 (674.03, 1892.00)
‡ 14 11.49 (8.24, 16.03)*** 0.95 (0.54, 1.37)*** 1274.69 (685.80, 1863.58)
Race/ethnicity
White (omitted) (omitted)
Black 0.56 (0.44, 0.71)*** - 0.30 ( - 0.60, - 0.00)* - 399.09 ( - 795.97, - 2.22)
Hispanic 0.63 (0.38, 1.07) 0.11 ( - 0.33, 0.55) 147.55 ( - 445.83, 740.94)
Other/unknown 1.40 (0.88, 2.24) 0.06 ( - 0.24, 0.37) 86.33 ( - 320.04, 492.69)
Insurance
Fee-for-service (FFS) only (omitted) (omitted)
Primary care case management (PCCM) only 0.71 (0.53, 0.95)* - 0.43 ( - 0.76, - 0.10)*** - 576.87 ( - 1028.11, - 125.64)
Switches between FFS & PCCM 0.80 (0.62, 1.04) - 0.46 ( - 0.75, - 0.16) - 612.57 ( - 1019.25, - 205.89)
*Significant at £ 0.05, **significant at < 0.01, ***significant at < 0.001.
MRX=Medicaid Rx, NSCAW=National Survey of Child and Adolescent Well-Being, CI=Confidence Interval, GLM=Generalized Linear Model
Note: Predictive margins reflect the mean effect for child observations with drug expenditures in any of the MRX categories in Table 1. They are the
marginal effect for Part II of the model.
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ultimately reunited with their families stay a median of a year in the
child welfare system; however, children who are ultimately adop-
ted stay a median of 35 months (Wildfire et al. 2007). Even after
departure from foster care, children maintain Medicaid eligibility
for a mean of 3 months (Raghavan et al. 2009). Consequently,
cumulative median Medicaid expenditures on medications can
approximate $1482 at a lower bound, with a large proportion of
children costing Medicaid agencies several thousand dollars
throughout their stay in the child welfare system.
Our findings also suggest that cost containment for pharma-
ceuticals can be achieved by focusing on particular drug classes.
The principal cost drivers in our study were amphetamine-type
stimulants and antidepressants, both of which may be suitable
targets for a focused cost-containment policy. One such policy that
Medicaid agencies have deployed to monitor medication spending
is prior authorization, which requires additional patient-level in-
formation prior to approval of reimbursement for certain pharma-
ceutical products (Tilly and Elam 2003). These findings suggest
that instead of a global medication use prior authorization policy
regime, Medicaid’s efforts may be better served by focusing nar-
rowly on these two drug classes. Such a narrowing of regulation
may reduce unintended consequences of prior authorization pro-
grams on access to needed services (West et al. 2009), and is in
keeping with reviews suggesting that prior authorization is least
associated with undesirable clinical outcomes when it is carefully
targeted at medications for which generics or alternatives are easily
available (Green et al. 2010). There is a risk that such a policy may
result in inappropriate underutilization of amphetamine-type
stimulants and antidepressants for children who need them; any
such policy design will, therefore, have to carefully monitor out-
comes for all children subject to such a policy regime.
Also, children in PCCM plans incurred average medication ex-
penditures that were $577 less than those of children in FFS plans.
This finding is perhaps a financial endorsement of the medical
home models developing within Medicaid programs, which share
several key characteristics in common with PCCM plans. Medicaid
agencies should consider accelerating movement of child welfare-
involved children into medical home models. Coordinating care
for such high-use children within medical homes is not only likely
to improve the quality of their care, but also to reduce the over-
all costs of their care, at least regarding psychotropic medication
expenditures.
Finally, a child with an externalizing CBCL score in the clinical
range costs Medicaid an additional $853 in psychotropic drugs
annually relative to a child with medication use who has a low
externalizing score. Compared with other instruments available
within NSCAW (not shown), this instrument is perhaps the single
strongest predictor of Medicaid expenditures. Extending the use of
the CBCL as a screening tool to all child welfare Medicaid bene-
ficiaries may give Medicaid agencies greater predictability on
Table 3. Two-Part Regression Model of Cumulative Drug Expenditures (MRX Classification),






for expenditure if > $0
Predictive
margin (Part II)
for expenditure if > $0
Male 2.01 (1.44, 2.81)*** 0.37 (0.08, 0.65)* 572.13 (114.35, 1029.91)
Age
3–5 (omitted) (omitted)
6–11 5.28 (3.07, 9.06)*** 0.45 ( - 0.03, 0.93) 699.07 ( - 56.95, 1455.09)
12–13 6.62 (3.63, 12.08)*** 0.54 (0.02, 1.05)* 834.73 (23.05, 1646.40)
‡ 14 6.13 (3.35, 11.20)*** 0.59 (0.07, 1.10)* 910.64 (98.90, 1722.39)
Race/ethnicity
White (omitted) (omitted)
Black 0.54 (0.36, 0.83)** - 0.49 ( - 0.81, - 0.17)** - 760.37 ( - 1281.26, - 239.47)
Hispanic 0.76 (0.35, 1.62) 0.18 ( - 0.36, 0.71) 278.37 ( - 556.92, 1113.67)
Other/unknown 0.99 (0.48, 2.04) - 0.11 ( - 0.61, 0.40) - 163.29 ( - 948.37, 621.80)
Insurance
Fee-for-service (FFS) only (omitted) (omitted)
Primary care case management (PCCM) only 0.70 (0.44, 1.11) - 0.16 ( - 0.54, 0.23) - 243.29 ( - 842.47, 355.88)
Switches between FFS & PCCM 0.90 (0.60, 1.33) - 0.14 ( - 0.47, 0.19) - 217.68 ( - 725.08, 289.72)
Out-of-home care vs. in-home care 1.94 (1.34, 2.81)*** 0.17 ( - 0.12, 0.47) 269.85 ( - 182.15, 721.85)
Fair or poor health vs. excellent or good health 1.70 (1.05, 2.73)* 0.25 ( - 0.17, 0.66) 382.06 ( - 271.37, 1035.48)
Rural vs. urban 1.02 (0.69, 1.50) - 0.26 ( - 0.59, 0.07) - 401.28 ( - 922.38, 119.83)
CBCL Score
Externalizing t score ‡ 64 vs. t score< 64 4.32 (3.02, 6.19)*** 0.55 (0.27, 0.83)*** 853.05 (366.16, 1339.93)
Internalizing t score ‡ 64 vs. t score < 64 1.32 (0.92, 1.91) 0.15 ( - 0.11, 0.41) 230.31 ( - 170.63, 631.25)
Maltreatment history
Physical abuse 1.44 (1.02, 2.03)* 0.01 ( - 0.3, 0.32) 18.07 ( - 460.07, 496.20)
Sexual abuse 1.46 (0.91, 2.33) 0.09 ( - 0.31, 0.48) 133.99 ( - 479.42, 747.39)
Neglect 0.82 (0.5, 1.35) - 0.29 ( - 0.67, 0.08) - 456.53 ( - 1048.84, 135.78)
Abandonment 1.28 (0.73, 2.23) 0.24 ( - 0.14, 0.61) 365.20 ( - 209.94, 940.34)
*Significant at < 0.05, **significant at < 0.01, ***significant at < 0.001
MRX=Medicaid Rx, NSCAW=National Survey of Child and Adolescent Well-Being, CI=Confidence Interval, GLM =Generalized Linear Model,
CBCL=Child Behavior Check List
Note: Predictive margins reflect the mean effect for child observations with drug expenditures in any of the MRX categories in Table 1. They are the
marginal effect for Part II of the model.
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identifying and resourcing high-use children. The California
Evidence-Based Clearinghouse for Child Welfare, a group that
disseminates evidence-based practices to child welfare agencies,
gives the CBCL its highest rating of A (California Evidence-Based
Clearinghouse for Child Welfare 2010), and our findings of-
fer Medicaid agencies a financial reason for its adoption as a
population-level screening instrument.
Our study is subject to a few limitations. The design of our data
linkage and our inability to use weights means that our results
cannot be generalized to a nationally representative sample of
children in child welfare – our data are convenience samples of
children in 14 states. Second, we used Medicaid eligibility codes to
identify a comparison sample of child Medicaid beneficiaries
without foster care involvement. We do not have definitive infor-
mation on child welfare involvement for these children. It is pos-
sible, therefore, that some of these children may have been
maltreated, in which case our estimates of the magnitude of ex-
penditure differences between NSCAW children and comparison
children is conservatively biased. On the other hand, our compar-
ison group has a higher proportion of SCHIP-eligible children.
These may have a lower average rate of medication use. Hence, our
comparative estimates must be approached with caution. Third, in
some states in our sample, such as California, increased managed
care penetration and lack of availability of shadow claims pre-
cluded our ability to fully capture expenditures. Hence, our data are
only reflective of children in non-managed Medicaid systems,
which form the largest type of payment systems for children in
child welfare (Raghavan and Leibowitz 2007), and were the
dominant plan types for child welfare children in our sample.
Fourth, concerns in the literature with the validity of diagnoses in
Medicaid claims data led us to focus on validated instruments
instead of particular diagnostic categories (Crystal et al. 2007).
Finally, our data only reflect Medicaid expenditures generated by a
paid claim; our results are not reflective of the true societal costs of
psychotropic drugs for these children.
Conclusion
Despite these limitations, this first-ever linkage between survey
data and Medicaid claims data at a national level provides many
new insights to Medicaid policymakers on better predicting psy-
chotropic medication expenditures among a highly vulnerable
population. Planning for these expenditures, and ensuring that the
needs of the most emotionally disturbed children are adequately
resourced, is of critical important to Medicaid agencies as they
attempt to resource care for children in the child welfare system
within an increasingly unstable and uncertain fiscal climate.
Clinical Significance
This first-ever linkage between a national survey and Medicaid
claims provides new estimates on the magnitude of expenditures
incurred on psychotropic medications for the care of maltreated
children. It provides new information on the types of medications
that are the primary drivers of these increased expenditures, and
provides Medicaid policymakers with information on ways to un-
dertake cost containment, especially as health reform efforts get
underway.
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